Rationally Designed Immune
Therapeutics for Endogenous
Retroviral Targets
in Cancer and Aging

Rationally Designed
Immune Therapeutics
for Endogenous Retroviral Targets
in Cancer and Aging

The human genomes encodes human endogenous retroviral (HERVs) genes left over from ancient viral infections. HERVs are silenced in healthy cells but are turned on as result of the aging process and in cancer cells.

HERVs have escaped, until now, immune targeting as they are recognized as self until too late in disease.

Our proprietary platform can now target HERVs and engage both cellular and humoral immunity against these previously undruggable antigens.

This represents a potential new paradigm in increasing longevity and treating cancer

Meet the team

At Hervolution, we challenge biotechnology as we know it by shifting the paradigm in cancer immunotherapy. We have established a great team of scientists, advisors and entrepreneurs with long-standing experience to drive our research every day.

MGT_JR_Coleman
J. Robert Coleman, PhD, MBA
Chief Executive Officer
Peter-Holst
Peter Holst, MD, PhD
Chief Scientific Officer
Hamina-Patel
Hamina Patel, MD, PhD
Chief Medical Officer

Latest news

Robert Langer
pexels-photo-3786247
pexels-photo-259251
flight-sky-earth-space